Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer

Luca Gianni, Anna Lladó, Giulia Bianchi, Javier Cortes, Pirkko-Liisa Kellokumpu-Lehtinen, David A Cameron, David Miles, Stefania Salvagni, Andrew Wardley, Jean-Charles Goeminne, Veronica Hersberger, José Baselga

Research output: Contribution to journalArticlepeer-review

Abstract

Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the antitumor activity and safety profile of pertuzumab monotherapy in patients with HER2-negative metastatic breast cancer. The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored.
Original languageEnglish
Pages (from-to)1131-7
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number7
DOIs
Publication statusPublished - 2010

Keywords / Materials (for Non-textual outputs)

  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Breast Neoplasms
  • Dimerization
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Metastasis
  • Receptor, erbB-2
  • Ventricular Function, Left

Fingerprint

Dive into the research topics of 'Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer'. Together they form a unique fingerprint.

Cite this